Patient preferences could influence mortality requirements in heart failure

Companies that were seeking more clarity on mortality requirements of heart failure therapies that provide symptomatic benefit didn't get it at a Friday workshop hosted by FDA. Instead, doctors and patients suggested that multiple factors could affect exactly how much mortality risk should be ruled out, but most do not see a viable commercial path for a drug that improves symptoms but has mortality risks.

FDA held the public workshop to discuss its draft guidance

Read the full 749 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE